uniqure.com (QURE): שווי פעילות לרווח לפני ריבית, מסים ופחת

uniQure N.V. is a Dutch biotech leader based in the US that develops innovative genetic medicines. This GURU.Markets chart of the company's EV/EBITDA ratio illustrates the market response, where the value 0.00 reflects the metric's balance. The business model relies on revenues from Hemgenix to fund the development of new drugs, while unique patents on delivery vectors create an insurmountable barrier for competitors.

When constructing a long-term portfolio, asset screening requires comparing the total enterprise value of a business with its operational profitability before taxes, depreciation, and amortization. The current value of 0.00 reflects the market valuation of uniQure N.V. (QURE) relative to its ability to generate income, which is critical for the non-cyclical gene therapy sector dependent on venture capital, and is clearly interpreted through the company's EV/EBITDA multiple chart.